Detalhe da pesquisa
1.
Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy.
Ann Neurol
; 83(6): 1133-1146, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29679388
2.
Targeting of protein translation as a new treatment paradigm for prostate cancer.
Curr Opin Oncol
; 29(3): 210-220, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28282343
3.
The Novel Mnk1/2 Degrader and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis.
Cancers (Basel)
; 11(3)2019 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30832411
4.
Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3ß Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo.
Cancers (Basel)
; 11(11)2019 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31653008
5.
The retinamide VNLG-152 inhibits f-AR/AR-V7 and MNK-eIF4E signaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth.
FEBS J
; 285(6): 1051-1063, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29323792
6.
Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets.
J Steroid Biochem Mol Biol
; 166: 16-27, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27481707
7.
Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3ß-Imidazole Carbamate.
ACS Med Chem Lett
; 7(7): 708-13, 2016 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27437082
8.
Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
Oncotarget
; 6(5): 3195-210, 2015 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25605250
9.
Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.
Oncotarget
; 6(29): 27440-60, 2015 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26196320
10.
Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenografts in mice.
J Med Chem
; 58(4): 1900-14, 2015 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-25634130
11.
First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines.
Oncotarget
; 5(2): 530-43, 2014 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24504069
12.
VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats.
Eur J Pharmacol
; 734: 98-104, 2014 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-24726842
13.
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
J Med Chem
; 56(12): 4880-98, 2013 Jun 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-23713567